Delivery of Local Therapeutics to the brain: Working Toward Advancing Treatment for Malignant Gliomas

References

• Dubrow R Darefsky AS . Demographic variation in incidence of adult glioma by subtype, United States, 1992–2007. BMC Cancer11, 325 (2011).
   PubMed Web of Science ®Google Scholar
• Tait MJ Petrik V Loosemore A Bell BA Papadopoulos MC . Survival of patients with glioblastoma multiforme has not improved between 1993 and 2004: analysis of 625 cases. Br. J. Neurosurg.21 (5), 496–500 (2007).
   PubMed Web of Science ®Google Scholar
• Chaichana K Zamora-Berridi G Camara-Quintana J Quinones-Hinojosa A . Neurosphere assays: growth factors and hormone differences in tumor and nontumor studies. Stem Cells24 (12), 2851–2857 (2006).
   PubMed Web of Science ®Google Scholar
• Chaichana KL Capilla-Gonzalez V Gonzalez-Perez O et al. Preservation of glial cytoarchitecture from ex vivo human tumor and non-tumor cerebral cortical explants: a human model to study neurological diseases. J. Neurosci. Methods164 (2), 261–270 (2007).
   PubMed Web of Science ®Google Scholar
• Chaichana KL Guerrero-Cazares H Capilla-Gonzalez V et al. Intra-operatively obtained human tissue: protocols and techniques for the study of neural stem cells. J. Neurosci. Methods180 (1), 116–125 (2009).
   PubMed Web of Science ®Google Scholar
• Quinones-Hinojosa A Chaichana K . The human subventricular zone: a source of new cells and a potential source of brain tumors. Exp. Neurol.205 (2), 313–324 (2007).
   PubMed Web of Science ®Google Scholar
• De Bock M Vandenbroucke RE Decrock E Culot M Cecchelli R Leybaert L . A new angle on blood-CNS interfaces: a role for connexins?FEBS Lett.588 (8), 1259–1270 (2014).
   PubMed Web of Science ®Google Scholar
• Lesniak MS Brem H . Targeted therapy for brain tumours. Nat. Rev. Drug. Discov.3 (6), 499–508 (2004).
   PubMed Web of Science ®Google Scholar
• Raza SM Pradilla G Legnani FG et al. Local delivery of antineoplastic agents by controlled-release polymers for the treatment of malignant brain tumours. Expert Opin. Biol. Ther.5 (4), 477–494 (2005).
   PubMed Web of Science ®Google Scholar
• Voges J Reszka R Gossmann A et al. Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann. Neurol.54 (4), 479–487 (2003).
   PubMed Web of Science ®Google Scholar
• Walter KA Tamargo RJ Olivi A Burger PC Brem H . Intratumoral chemotherapy. Neurosurgery37 (6), 1128–1145 (1995).
   PubMed Web of Science ®Google Scholar
• Farra R Sheppard NF Jr McCabe L et al. First-in-human testing of a wirelessly controlled drug delivery microchip. Sci. Transl. Med.4 (122), 122ra21 (2012).
   PubMed Web of Science ®Google Scholar
• Scott AW Tyler BM Masi BC et al. Intracranial microcapsule drug delivery device for the treatment of an experimental gliosarcoma model. Biomaterials32 (10), 2532–2539 (2011).
   PubMed Web of Science ®Google Scholar
• Chaichana K Parker S Olivi A Quinones-Hinojosa A . A proposed classification system that projects outcomes based on preoperative variables for adult patients with glioblastoma multiforme. J. Neurosurg.112 (5), 997–1004 (2010).
   PubMed Web of Science ®Google Scholar
• Chaichana KL Cabrera-Aldana EE Jusue-Torres I et al. When gross total resection of a glioblastoma is possible, how much resection should be achieved? World Neurosurg. 82 (1-2), e257–e265 (2014).
   PubMed Web of Science ®Google Scholar
• Chaichana KL Chaichana KK Olivi A et al. Surgical outcomes for older patients with glioblastoma multiforme: preoperative factors associated with decreased survival. Clinical article. J. Neurosurg.114 (3), 587–594 (2011).
   PubMed Web of Science ®Google Scholar
• Chaichana KL Garzon-Muvdi T Parker S et al. Supratentorial glioblastoma multiforme: the role of surgical resection versus biopsy among older patients. Ann. Surg. Oncol.18 (1), 239–245 (2011).
   PubMed Web of Science ®Google Scholar
• Chaichana KL McGirt MJ Frazier J Attenello F Guerrero-Cazares H Quinones-Hinojosa A . Relationship of glioblastoma multiforme to the lateral ventricles predicts survival following tumor resection. J. Neurooncol.89 (2), 219–224 (2008).
   PubMed Web of Science ®Google Scholar
• Chaichana KL Parker SL Mukherjee D Cheng JS Gokaslan ZL McGirt MJ . Assessment of the extent of surgical resection as a predictor of survival in patients with primary osseous spinal neoplasms. Clin. Neurosurg.58, 117–121 (2011).
   PubMedGoogle Scholar
• Lacroix M Abi-Said D Fourney DR et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J. Neurosurg.95 (2), 190–198 (2001).
   PubMed Web of Science ®Google Scholar
• Lamborn KR Chang SM Prados MD . Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro. Oncol.6 (3), 227–235 (2004).
   PubMed Web of Science ®Google Scholar
• Laws ER Parney IF Huang W et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J. Neurosurg.99 (3), 467–473 (2003).
   PubMed Web of Science ®Google Scholar
• McGirt MJ Chaichana KL Gathinji M et al. Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J. Neurosurg.110 (1), 156–162 (2009).
   PubMed Web of Science ®Google Scholar
• McGirt MJ Mukherjee D Chaichana KL Than KD Weingart JD Quinones-Hinojosa A . Association of surgically acquired motor and language deficits on overall survival after resection of glioblastoma multiforme. Neurosurgery65 (3), 463–469 ; discussion 469–470 (2009).
   PubMed Web of Science ®Google Scholar
• Stupp R Mason WP van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med.352 (10), 987–996 (2005).
   PubMed Web of Science ®Google Scholar
• Chaichana KL Zadnik P Weingart JD et al. Multiple resections for patients with glioblastoma: prolonging survival. J. Neurosurg.118 (4), 812–820 (2013).
   PubMed Web of Science ®Google Scholar
• Chaichana KL Jusue-Torres I Navarro-Ramirez R et al. Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro. Oncol.16 (1), 113–122 (2014).
   PubMed Web of Science ®Google Scholar
• Chaichana KL Kosztowski T Niranjan A et al. Prognostic significance of contrast-enhancing anaplastic astrocytomas in adults. J. Neurosurg.113 (2), 286–292 (2010).
   PubMed Web of Science ®Google Scholar
• Sathornsumetee S Rich JN . New treatment strategies for malignant gliomas. Expert Rev. Anticancer Ther.6 (7), 1087–1104 (2006).
   PubMed Web of Science ®Google Scholar
• Brem H Piantadosi S Burger PC et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The polymer-brain tumor treatment group. Lancet345 (8956), 1008–1012 (1995).
   PubMed Web of Science ®Google Scholar
• Chaichana KL Halthore AN Parker SL et al. Factors involved in maintaining prolonged functional independence following supratentorial glioblastoma resection. Clinical article. J. Neurosurg.114 (3), 604–612 (2011).
   PubMed Web of Science ®Google Scholar
• Chaichana KL Zaidi H Pendleton C et al. The efficacy of carmustine wafers for older patients with glioblastoma multiforme: prolonging survival. Neurol. Res.33 (7), 759–764 (2011).
   PubMed Web of Science ®Google Scholar
• Chang CH Horton J Schoenfeld D et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint radiation therapy oncology group and eastern cooperative oncology group study. Cancer52 (6), 997–1007 (1983).
   PubMed Web of Science ®Google Scholar
• Chang SM Parney IF McDermott M et al. Perioperative complications and neurological outcomes of first and second craniotomies among patients enrolled in the glioma outcome project. J. Neurosurg.98 (6), 1175–1181 (2003).
   PubMed Web of Science ®Google Scholar
• McGirt MJ Than KD Weingart JD et al. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J. Neurosurg.110 (3), 583–588 (2009).
   PubMed Web of Science ®Google Scholar
• Sanai N Polley MY McDermott MW Parsa AT Berger MS . An extent of resection threshold for newly diagnosed glioblastomas. J. Neurosurg.115 (1), 3–8 (2011).
   PubMed Web of Science ®Google Scholar
• Chaichana KL Pendleton C Chambless L et al. Multi-institutional validation of a preoperative scoring system which predicts survival for patients with glioblastoma. J. Clin. Neurosci.20 (10), 1422–1426 (2013).
   PubMed Web of Science ®Google Scholar
• Hegi ME Diserens AC Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med.352 (10), 997–1003 (2005).
   PubMed Web of Science ®Google Scholar
• Parsons DW Jones S Zhang X et al. An integrated genomic analysis of human glioblastoma multiforme. Science321 (5897), 1807–1812 (2008).
   PubMed Web of Science ®Google Scholar
• Walker MD Alexander E Jr Hunt WE et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J. Neurosurg.49 (3), 333–343 (1978).
   PubMed Web of Science ®Google Scholar
• Hochberg FH Pruitt A . Assumptions in the radiotherapy of glioblastoma. Neurology30 (9), 907–911 (1980).
   PubMed Web of Science ®Google Scholar
• Brem H Ewend MG Piantadosi S Greenhoot J Burger PC Sisti M . The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial. J. Neurooncol.26 (2), 111–123 (1995).
   PubMed Web of Science ®Google Scholar
• Valtonen S Timonen U Toivanen P et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery41 (1), 44–48 ; discussion 48–49 (1997).
   PubMed Web of Science ®Google Scholar
• Westphal M Hilt DC Bortey E et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro. Oncol.5 (2), 79–88 (2003).
   PubMed Web of Science ®Google Scholar
• Westphal M Ram Z Riddle V Hilt D Bortey E . Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta. Neurochir. (Wien)148 (3), 269–275 ; discussion 275 (2006).
   PubMed Web of Science ®Google Scholar
• Gallia GL Brem S Brem H . Local treatment of malignant brain tumors using implantable chemotherapeutic polymers. J. Natl Compr. Canc. Netw.3 (5), 721–728 (2005).
   PubMedGoogle Scholar
• Dandy WE . Removal of right cerebral hemisphere for certain tumors with hemiplegia. JAMA90 (11), 823–825 (1928).
   Google Scholar
• Metcalfe SE Grant R . Biopsy versus resection for malignant glioma. Cochrane Database Syst. Rev.3, CD002034 (2001).
   Google Scholar
• Andersen AP . Postoperative irradiation of glioblastomas. Results in a randomized series. Acta Radiol. Oncol. Radiat. Phys. Biol.17 (6), 475–484 (1978).
   PubMed Web of Science ®Google Scholar
• Bleehen NM Stenning SP . A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. Br. J. Cancer64 (4), 769–774 (1991).
   PubMed Web of Science ®Google Scholar
• Garden AS Maor MH Yung WK et al. Outcome and patterns of failure following limited-volume irradiation for malignant astrocytomas. Radiother. Oncol.20 (2), 99–110 (1991).
   PubMed Web of Science ®Google Scholar
• Molenaar RJ Verbaan D Lamba S et al. The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone. Neuro. Oncol.16 (9), 1263–73 (2014).
   PubMed Web of Science ®Google Scholar
• Esteller M Garcia-Foncillas J Andion E et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med.343 (19), 1350–1354 (2000).
   PubMed Web of Science ®Google Scholar
• Groothuis DR Fischer JM Lapin G Bigner DD Vick NA . Permeability of different experimental brain tumor models to horseradish peroxidase. J. Neuropathol. Exp. Neurol.41 (2), 164–185 (1982).
   PubMed Web of Science ®Google Scholar
• Neuwelt EA Barnett PA Bigner DD Frenkel EP . Effects of adrenal cortical steroids and osmotic blood-brain barrier opening on methotrexate delivery to gliomas in the rodent: the factor of the blood-brain barrier. Proc. Natl Acad. Sci. USA79 (14), 4420–4423 (1982).
   PubMed Web of Science ®Google Scholar
• Liu HL Fan CH Ting CY Yeh CK . Combining microbubbles and ultrasound for drug delivery to brain tumors: current progress and overview. Theranostics4 (4), 432–444 (2014).
   PubMed Web of Science ®Google Scholar
• Riva P Franceschi G Frattarelli M et al. 131I radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma–phase I and II study. Acta Oncol.38 (3), 351–359 (1999).
   PubMed Web of Science ®Google Scholar
• Gaspar LE Zamorano LJ Shamsa F Fontanesi J Ezzell GE Yakar DA . Permanent 125iodine implants for recurrent malignant gliomas. Int. J. Radiat. Oncol. Biol. Phys.43 (5), 977–982 (1999).
   PubMed Web of Science ®Google Scholar
• Torres LA Coca MA Batista JF et al. Biodistribution and internal dosimetry of the 188Re-labelled humanized monoclonal antibody anti-epidemal growth factor receptor, nimotuzumab, in the locoregional treatment of malignant gliomas. Nucl. Med. Commun.29 (1), 66–75 (2008).
   PubMed Web of Science ®Google Scholar
• Bartolomei M Mazzetta C Handkiewicz-Junak D et al. Combined treatment of glioblastoma patients with locoregional pre-targeted 90Y-biotin radioimmunotherapy and temozolomide. Q J Nucl. Med. Mol. Imaging48 (3), 220–228 (2004).
   PubMed Web of Science ®Google Scholar
• Paganelli G Bartolomei M Ferrari M et al. Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results. Cancer Biother. Radiopharm.16 (3), 227–235 (2001).
   PubMed Web of Science ®Google Scholar
• Prados MD McDermott M Chang SM et al. Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration: a phase I/II multi-institutional trial. J. Neurooncol.65 (3), 269–278 (2003).
   PubMed Web of Science ®Google Scholar
• Goetz C Riva P Poepperl G et al. Locoregional radioimmunotherapy in selected patients with malignant glioma: experiences, side effects and survival times. J. Neurooncol.62 (3), 321–328 (2003).
   PubMed Web of Science ®Google Scholar
• Jung G Brandl M Eisner W et al. Local immunotherapy of glioma patients with a combination of 2 bispecific antibody fragments and resting autologous lymphocytes: evidence for in situ t-cell activation and therapeutic efficacy. Int. J. Cancer91 (2), 225–230 (2001).
   PubMed Web of Science ®Google Scholar
• Quattrocchi KB Miller CH Cush S et al. Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas. J. Neurooncol.45 (2), 141–157 (1999).
   PubMed Web of Science ®Google Scholar
• Bigner DD Brown MT Friedman AH et al. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. J. Clin. Oncol.16 (6), 2202–2212 (1998).
   PubMed Web of Science ®Google Scholar
• Patchell RA Regine WF Ashton P et al. A phase I trial of continuously infused intratumoral bleomycin for the treatment of recurrent glioblastoma multiforme. J. Neurooncol.60 (1), 37–42 (2002).
   PubMed Web of Science ®Google Scholar
• Boiardi A Eoli M Salmaggi A et al. New approach in delivering chemotherapy: locoregional treatment for recurrent glioblastoma (rGBM). J. Exp. Clin. Cancer Res.22 (4 Suppl.), 123–127 (2003).
   PubMed Web of Science ®Google Scholar
• Lang FF Bruner JM Fuller GN et al. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J. Clin. Oncol.21 (13), 2508–2518 (2003).
   PubMed Web of Science ®Google Scholar
• Ferroli P Broggi M Franzini A et al. Surgifoam and mitoxantrone in the glioblastoma multiforme postresection cavity: the first step of locoregional chemotherapy through an ad hoc-placed catheter: technical note. Neurosurgery59 (2), E433–E434 ; discussion E433-E434 (2006).
   PubMedGoogle Scholar
• Boiardi A Silvani A Eoli M et al. Treatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival? J. Neurooncol. 88 (1), 105–113 (2008).
   PubMed Web of Science ®Google Scholar
• Voulgaris S Partheni M Karamouzis M Dimopoulos P Papadakis N Kalofonos HP . Intratumoral doxorubicin in patients with malignant brain gliomas. Am. J. Clin. Oncol.25 (1), 60–64 (2002).
   PubMed Web of Science ®Google Scholar
• Boiardi A Eoli M Salmaggi A et al. Efficacy of intratumoral delivery of mitoxantrone in recurrent malignant glial tumours. J. Neurooncol.54 (1), 39–47 (2001).
   PubMed Web of Science ®Google Scholar
• Boiardi A Silvani A Pozzi A Fariselli L Broggi G Salmaggi A . Interstitial chemotherapy plus systemic chemotherapy for glioblastoma patients: improved survival in sequential studies. J. Neurooncol.41 (2), 151–157 (1999).
   PubMed Web of Science ®Google Scholar
• Boiardi A Eoli M Pozzi A Salmaggi A Broggi G Silvani A . Locally delivered chemotherapy and repeated surgery can improve survival in glioblastoma patients. Ital. J. Neurol. Sci.20 (1), 43–48 (1999).
   PubMedGoogle Scholar
• Oshiro S Tsugu H Komatsu F et al. Evaluation of intratumoral administration of tumor necrosis factor-alpha in patients with malignant glioma. Anticancer Res.26 (6A), 4027–4032 (2006).
   PubMed Web of Science ®Google Scholar
• Koch D Hundsberger T Boor S Kaina B . Local intracerebral administration of O(6)-benzylguanine combined with systemic chemotherapy with temozolomide of a patient suffering from a recurrent glioblastoma. J. Neurooncol.82 (1), 85–89 (2007).
   PubMed Web of Science ®Google Scholar
• Nakagawa K Kamezaki T Shibata Y Tsunoda T Meguro K Nose T . Effect of lymphokine-activated killer cells with or without radiation therapy against malignant brain tumors. Neurol. Med. Chir. (Tokyo)35 (1), 22–27 (1995).
   PubMedGoogle Scholar
• Hadaczek P Mirek H Berger MS Bankiewicz K . Limited efficacy of gene transfer in herpes simplex virus-thymidine kinase/ganciclovir gene therapy for brain tumors. J. Neurosurg.102 (2), 328–335 (2005).
   PubMed Web of Science ®Google Scholar
• Boiardi A Salmaggi A Pozzi A Broggi G Silvani A . Interstitial chemotherapy with mitoxantrone in recurrent malignant glioma: preliminary data. J. Neurooncol.27 (2), 157–162 (1996).
   PubMed Web of Science ®Google Scholar
• Bobo RH Laske DW Akbasak A Morrison PF Dedrick RL Oldfield EH . Convection-enhanced delivery of macromolecules in the brain. Proc. Natl Acad. Sci. USA91 (6), 2076–2080 (1994).
   PubMed Web of Science ®Google Scholar
• Lieberman DM Laske DW Morrison PF Bankiewicz KS Oldfield EH . Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J. Neurosurg.82 (6), 1021–1029 (1995).
   PubMed Web of Science ®Google Scholar
• Kunwar S Prados MD Chang SM et al. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J. Clin. Oncol.25 (7), 837–844 (2007).
   PubMed Web of Science ®Google Scholar
• Sampson JH Akabani G Friedman AH et al. Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies. Neurosurg. Focus20 (4), E14 (2006).
   PubMedGoogle Scholar
• Tanner PG Holtmannspotter M Tonn JC Goldbrunner R . Effects of drug efflux on convection-enhanced paclitaxel delivery to malignant gliomas: technical note. Neurosurgery61 (4), E880–E882 ; discussion E882 (2007).
   PubMed Web of Science ®Google Scholar
• Varenika V Dickinson P Bringas J et al. Detection of infusate leakage in the brain using real-time imaging of convection-enhanced delivery. J. Neurosurg.109 (5), 874–880 (2008).
   PubMed Web of Science ®Google Scholar
• Bruce JN Fine RL Canoll P et al. Regression of recurrent malignant gliomas with convection-enhanced delivery of topotecan. Neurosurgery69 (6), 1272–1279 ; discussion 1279–1280 (2011).
   PubMed Web of Science ®Google Scholar
• Saito R Sonoda Y Kumabe T Nagamatsu K Watanabe M Tominaga T . Regression of recurrent glioblastoma infiltrating the brainstem after convection-enhanced delivery of nimustine hydrochloride. J. Neurosurg. Pediatr.7 (5), 522–526 (2011).
   PubMed Web of Science ®Google Scholar
• Lidar Z Mardor Y Jonas T et al. Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. J. Neurosurg.100 (3), 472–479 (2004).
   PubMed Web of Science ®Google Scholar
• Carpentier A Metellus P Ursu R et al. Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study. Neuro. Oncol.12 (4), 401–408 (2010).
   PubMed Web of Science ®Google Scholar
• Patel SJ Shapiro WR Laske DW et al. Safety and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma: initial experience in 51 patients. Neurosurgery56 (6), 1243–1252 ; discussion 1252–1253 (2005).
   PubMed Web of Science ®Google Scholar
• Bogdahn U Hau P Stockhammer G et al. Targeted therapy for high-grade glioma with the TGF-beta2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro. Oncol.13 (1), 132–142 (2011).
   PubMed Web of Science ®Google Scholar
• Kunwar S Chang S Westphal M et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro. Oncol.12 (8), 871–881 (2010).
   PubMed Web of Science ®Google Scholar
• Boiardi A Eoli M Salmaggi A et al. Local drug delivery in recurrent malignant gliomas. Neurol. Sci.26 (Suppl. 1), S37–S39 (2005).
   PubMedGoogle Scholar
• Sampson JH Akabani G Archer GE et al. Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J. Neurooncol.65 (1), 27–35 (2003).
   PubMed Web of Science ®Google Scholar
• Brem H Mahaley MS Jr Vick NA et al. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J. Neurosurg.74 (3), 441–446 (1991).
   PubMed Web of Science ®Google Scholar
• Brem H Piantadosi S Burger PC et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet345 (8956), 1008–1012 (1995).
   PubMed Web of Science ®Google Scholar
• Olivi A Ewend MG Utsuki T et al. Interstitial delivery of carboplatin via biodegradable polymers is effective against experimental glioma in the rat. Cancer Chemother. Pharmacol.39 (1–2), 90–96 (1996).
   PubMed Web of Science ®Google Scholar
• Menei P Capelle L Guyotat J et al. Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of malignant glioma: a randomized phase II trial. Neurosurgery56 (2), 242–248 ; discussion 242–248 (2005).
   PubMed Web of Science ®Google Scholar
• Gref R Minamitake Y Peracchia MT Trubetskoy V Torchilin V Langer R . Biodegradable long-circulating polymeric nanospheres. Science263 (5153), 1600–1603 (1994).
   PubMed Web of Science ®Google Scholar
• Gabizon A Isacson R Libson E et al. Clinical studies of liposome-encapsulated doxorubicin. Acta Oncol.33 (7), 779–786 (1994).
   PubMed Web of Science ®Google Scholar
• Rhines LD Sampath P DiMeco F et al. Local immunotherapy with interleukin-2 delivered from biodegradable polymer microspheres combined with interstitial chemotherapy: a novel treatment for experimental malignant glioma. Neurosurgery52 (4), 872–879 ; discussion 879–880 (2003).
   PubMed Web of Science ®Google Scholar
• Olivi A Grossman SA Tatter S et al. Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a new approaches to brain tumor therapy CNS consortium trial. J. Clin. Oncol.21 (9), 1845–1849 (2003).
   PubMed Web of Science ®Google Scholar
• Fung LK Ewend MG Sills A et al. Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. Cancer Res.58 (4), 672–684 (1998).
   PubMed Web of Science ®Google Scholar
• Menei P Metellus P Parot-Schinkel E et al. Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience. Ann. Surg. Oncol.17 (7), 1740–1746 (2010).
   PubMed Web of Science ®Google Scholar
• Hart MG Grant R Garside R Rogers G Somerville M Stein K . Chemotherapy wafers for high grade glioma. Cochrane Database Syst. Rev.3, CD007294 (2011).
   Google Scholar
• Aoki T Nishikawa R Sugiyama K et al. A multicenter phase I/II study of the BCNU implant (Gliadel((R)) wafer) for Japanese patients with malignant gliomas. Neurol. Med. Chir. (Tokyo)54 (4), 290–301 (2014).
   PubMed Web of Science ®Google Scholar
• McGirt MJ Brem H . Carmustine wafers (Gliadel) plus concomitant temozolomide therapy after resection of malignant astrocytoma: growing evidence for safety and efficacy. Ann. Surg. Oncol.17 (7), 1729–1731 (2010).
   PubMed Web of Science ®Google Scholar
• Noel G Schott R Froelich S et al. Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas. Int. J. Radiat. Oncol. Biol. Phys.82 (2), 749–755 (2012).
   PubMed Web of Science ®Google Scholar
• Miglierini P Bouchekoua M Rousseau B Hieu PD Malhaire JP Pradier O . Impact of the per-operatory application of GLIADEL wafers (BCNU, carmustine) in combination with temozolomide and radiotherapy in patients with glioblastoma multiforme: efficacy and toxicity. Clin. Neurol. Neurosurg.114 (9), 1222–1225 (2012).
   PubMed Web of Science ®Google Scholar
• Pan E Mitchell SB Tsai JS . A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients. J. Neurooncol.88 (3), 353–357 (2008).
   PubMed Web of Science ®Google Scholar
• Salvati M D'Elia A Frati A Brogna C Santoro A Delfini R . Safety and feasibility of the adjunct of local chemotherapy with biodegradable carmustine (BCNU) wafers to the standard multimodal approach to high grade gliomas at first diagnosis. J. Neurosurg. Sci.55 (1), 1–6 (2011).
   PubMed Web of Science ®Google Scholar
• Lechapt-Zalcman E Levallet G Dugue AE et al. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide. Cancer118 (18), 4545–4554 (2012).
   PubMed Web of Science ®Google Scholar
• Gururangan S Cokgor L Rich JN et al. Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. Neuro. Oncol.3 (4), 246–250 (2001).
   PubMed Web of Science ®Google Scholar
• Salmaggi A Milanesi I Silvani A et al. Prospective study of carmustine wafers in combination with 6-month metronomic temozolomide and radiation therapy in newly diagnosed glioblastoma: preliminary results. J. Neurosurg.118 (4), 821–829 (2013).
   PubMed Web of Science ®Google Scholar
• McPherson CM Gerena-Lewis M Breneman JC Warnick RE . Results of phase I study of a multi-modality treatment for newly diagnosed glioblastoma multiforme using local implantation of concurrent BCNU wafers and permanent I-125 seeds followed by fractionated radiation and temozolomide chemotherapy. J. Neurooncol.108 (3), 521–525 (2012).
   PubMed Web of Science ®Google Scholar
• Quinn JA Jiang SX Carter J et al. Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme. Clin. Cancer Res.15 (3), 1064–1068 (2009).
   PubMed Web of Science ®Google Scholar
• Richards Grayson AC Choi IS Tyler BM et al. Multi-pulse drug delivery from a resorbable polymeric microchip device. Nat. Mater.2 (11), 767–772 (2003).
   PubMed Web of Science ®Google Scholar
• Santini JT Jr Cima MJ Langer R . A controlled-release microchip. Nature397 (6717), 335–338 (1999).
   PubMed Web of Science ®Google Scholar
• Tyler MA Sonabend AM Ulasov IV Lesniak MS . Vector therapies for malignant glioma: shifting the clinical paradigm. Expert Opin. Drug Deliv.5 (4), 445–458 (2008).
   PubMed Web of Science ®Google Scholar
• Tzeng SY Guerrero-Cazares H Martinez EE Sunshine JC Quinones-Hinojosa A Green JJ . Non-viral gene delivery nanoparticles based on poly(beta-amino esters) for treatment of glioblastoma. Biomaterials32 (23), 5402–5410 (2011).
   PubMed Web of Science ®Google Scholar
• Wirth T Samaranayake H Pikkarainen J Maatta AM Yla-Herttuala S . Clinical trials for glioblastoma multiforme using adenoviral vectors. Curr. Opin. Mol. Ther.11 (5), 485–492 (2009).
   PubMedGoogle Scholar
• Affronti ML Heery CR Herndon JE 2nd et al. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. Cancer115 (15), 3501–3511 (2009).
   PubMed Web of Science ®Google Scholar